Enhanced HIV infectivity and changes in GP120 conformation associated with viral incorporation of human leucocyte antigen class I molecules

AIDS

Volumn 13, Issue 15, 1999, Pages 2033-2042

  Cosma, Antonio ^a   Blanc, Dominique ^a   Braun, Josephine ^a   Quillent, Caroline ^a   Barassi, Claudia ^b   Moog, Christiane ^c   Klasen, Sandrine ^a   Spire, Bruno ^c   Scarlatti, Gabriella ^b   Pesenti, Elena ^b   Siccardi, Antonio G ^b   Beretta, Alberto ^a,d  

^a Ctr Integre Rech Biocliniques S   (France)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c INSERM   (France)

^d CIRBS   (France)

Author keywords

Entry; Envelope proteins; HLA class I; Receptor; Virus cell interaction

Indexed keywords

GLYCOPROTEIN GP 120; HLA ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; PHYTOHEMAGGLUTININ; VIRUS ENVELOPE PROTEIN;

ARTICLE; CONTROLLED STUDY; DNA TRANSFECTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPRECIPITATION; MONONUCLEAR CELL; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN CONFORMATION; VIRUS INFECTIVITY; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

CELL LINE; DNA, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; NEUTRALIZATION TESTS; POLYMERASE CHAIN REACTION; PRECIPITIN TESTS; VIRUS REPLICATION;

EID: 0032759331     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199910220-00005     Document Type: Article

References (26)

1. Moore JP, Trkola A, Dragic T. Co-receptors for HIV-1 entry [see comments]. Curr Opin Immunol 1997, 9:551-562.
2. Tremblay MJ, Fortin JF, Cantin R. The acquisition of host-encoded proteins by nascent HIV-1. Immunol Today 1998, 19:346-351.
3. Shimizu Y, DeMars R. Production of human cells expressing individual transferred HLA-A,-B,-C genes using an HLA-A,-B,-C null human cell line. J Immunol 1989, 142:3320-3328.
4. Wyatt R, Moore J, Accola M, Desjardin E, Robinson J, Sodroski J. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Virol 1995, 69:5723-5733.
5. Thiriart C, Francotte M, Cohen J, et al. Several antigenic determinants exposed on the gp120 moiety of HIV-1 gp160 are hidden on the mature gp120. J Immunol 1989, 143:1832-1836.
6. Moore JP, Sodroski J. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J Virol 1996, 70:1863-1872.
7. Akerblom L, Hinkula J, Broliden PA, et al. Neutralizing cross-reactive and non-neutralizing monoclonal antibodies to HIV-1 gp120. AIDS 1990, 4:953-960.
8. Setini A, Beretta A, De Santis C, et al. Distinctive features of the alpha 1-domain alpha helix of HLA-C heavy chains free of beta 2-microglobulin. Hum Immunol 1996, 46:69-81.
9. Wain-Hobson S, Sonigo P, Danos O, Cole S, Alizon M. Nucleotide sequence of the AIDS virus, LAV. Cell 1985, 40:9-17.
10. Adachi A, Gendelman HE, Koenig S, et al. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 1986, 59:284-291.
11. Spire B, Sire J, Zachar V, et al. Nucleotide sequence of HIV1-NDK: a highly cytopathic strain of the human immunodeficiency virus. Gene 1989, 81:275-284.
12. Moog C, Fleury HJ, Pellegrin I, Kirn A, Aubertin AM. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J Virol 1997, 71:3734-3741.
13. Charneau P, Mirambeau G, Roux P, Paulous S, Buc H, Clavel F. HIV-1 reverse transcription. A termination step at the center of the genome. J Mol Biol 1994, 241:651-662.
14. Gilljam G. Envelope glycoproteins of HIV-1, HIV-2, and SIV purified with Galanthus nivalis agglutinin induce strong immune responses. AIDS Res Hum Retroviruses 1993, 9:431-438.
15. Cosma A. Affinity biotinylation: nonradioactive method for specific selection and labeling of cellular proteins. Anal Biochem 1997, 252:10-14.
16. Cantin R, Fortin JF, Lamontagne G, Tremblay M. The presence of host-derived HLA-DR1 on human immunodeficiency virus type 1 increases viral infectivity. J Virol 1997, 71:1922-1930.
17. Rizzuto CD, Sodroski JG. Contribution of virion ICAM-1 to human immunodeficiency virus infectivity and sensitivity to neutralization. J Virol 1997, 71:4847-4851.
18. Trkola A, Dragic T, Arthos J, et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5 [see comments]. Nature 1996, 384:184-187.
19. Wu L, Gerard NP, Wyatt R, et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5 [see comments]. Nature 1996, 384:179-183.
20. Wyatt R, Kwong PD, Desjardins E, et al. The antigenic structure of the HIV gp120 envelope glycoprotein [see comments]. Nature 1998, 393:705-711.
21. Adachi A, Gendelman HE, Koenig S, et al. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 1986, 59:284-291.
22. Sawyer LS, Wrin MT, Crawford-Miksza L, et al. Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated. J Virol 1994, 68:1342-1349.
23. Carrington M, Nelson GW, Martin MP, et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage [In Process Citation]. Science 1999, 283:1748-1752.
24. Shiga H, Shioda T, Tomiyama H, et al. Identification of multiple HIV-1 cytotoxic T-cell epitopes presented by human leukocyte antigen B35 molecules. AIDS 1996, 10:1075-1083.
25. Johnson RP, Trocha A, Buchanan TM, Walker BD. Recognition of a highly conserved region of human immunodeficiency virus type 1 gp120 by an HLA-Cw4-restricted cytotoxic T-lymphocyte clone. J Virol 1993, 67:438-445.
26. Tomiyama H, Miwa K, Shiga H, et al. Evidence of presentation of multiple HIV-1 cytotoxic T lymphocyte epitopes by HLA-B*3501 molecules that are associated with the accelerated progression of AIDS. J Immunol 1997, 158:5026-5034.